Contributor: AI-Based Remote Monitoring for Age-Related Macular Degeneration: Promise, Progress, and Pitfalls

Why It Matters

The analysis pinpoints the economic break‑even points that will shape payer reimbursement and physician adoption, directly influencing the scalability of AI‑enabled remote monitoring in ophthalmology.

Key Takeaways

• hOCT saves costs only for patients receiving ≥8 anti‑VEGF injections annually
• Device fees and AI analysis outweigh savings with cheaper drugs like bevacizumab
• Physician review time drops 96% when scanning only the latest monthly image
• Clinical outcome data from DRCR Protocol AO will drive future reimbursement
• Home OCT’s 3×3 mm field limits detection compared with standard 6×6 mm scans

Pulse Analysis

Age‑related macular degeneration remains a leading cause of irreversible vision loss, and anti‑VEGF injections are the therapeutic backbone. In 2019 Medicare alone spent more than $4 billion on these agents, a figure that is set to rise as newer, higher‑dose drugs such as aflibercept 8 mg and faricimab enter the market. Home‑based optical coherence tomography, powered by artificial intelligence, promises to shift monitoring from the clinic to the patient’s home, potentially extending injection intervals and reducing office visits. This shift aligns with broader tele‑health trends but hinges on whether the technology can deliver cost‑effective care.

A recent economic model compares hOCT with standard in‑office monitoring using 2026 Medicare Part B payment rates. The study finds that hOCT becomes cost‑neutral only when patients receive at least eight injections per year of high‑priced agents and achieve a reduction of six to four injections annually, depending on the drug. For cheaper agents like bevacizumab, the device adds roughly $9,200 per patient per year, while for aflibercept 8 mg the excess is about $1,900. Physician workload also shifts: reviewing a single monthly scan cuts interpretation time by 96%, but scaling to larger patient panels still adds several hours of weekly reading burden.

These findings have immediate implications for payers and providers. Reimbursement policies will likely favor hOCT in narrowly defined high‑burden populations unless outcome‑driven trials, such as the DRCR Protocol AO, demonstrate superior visual‑acuity results. Positive efficacy data could justify higher spending by improving quality of life and reducing long‑term vision loss costs. Moreover, the analysis highlights systemic challenges—device fees, AI supervision, and liability concerns—that must be addressed before AI‑augmented monitoring can achieve mainstream adoption across ophthalmology and other specialties.